Skip to main content

Leadership

2007 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle  
12/10/07Emergent BioSolutions to Present at Upcoming Investor Conferences Printer Friendly Version
11/19/07U.S. Department of Health and Human Services Remains Committed to Procurement of BioThrax(R) Under Current Contract Printer Friendly Version
11/12/07Emergent BioSolutions to Lead a United States Delegation to the United States - India Business Council (a Subsidiary of the US Chamber of Commerce) Health Summit in India Printer Friendly Version
11/08/07Emergent BioSolutions Announces Update on Department of Defense Procurement Strategy For BioThrax(R) (Anthrax Vaccine Adsorbed) Printer Friendly Version
11/05/07Emergent BioSolutions Completes Clinical Study in Support of a Post-Exposure Prophylaxis Indication for BioThrax(R) (Anthrax Vaccine Adsorbed) Printer Friendly Version
11/02/07Emergent BioSolutions Reports Financial Results for Third Quarter 2007 Printer Friendly Version
10/29/07Emergent BioSolutions to Present at November Investor Conferences Printer Friendly Version
10/22/07Emergent BioSolutions to Release Third Quarter 2007 Financial Results on November 2, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments Printer Friendly Version
10/18/07Emergent BioSolutions Announces Dr. Stephen Lockhart Joins Company to Lead Commercial Product Development Subsidiary Printer Friendly Version
10/10/07Emergent BioSolutions' Typhoid Vaccine Candidate Achieves Endpoints in Phase II Clinical Study Printer Friendly Version
10/09/07Emergent BioSolutions Announces the Appointment of Denise Landry as Senior Vice President, Quality Printer Friendly Version
10/03/07Emergent BioSolutions to Present at BIO InvestorForum 2007 Printer Friendly Version
10/02/07Emergent BioSolutions Completes First Delivery of BioThrax(R) (Anthrax Vaccine Adsorbed) to The Department of Health and Human Services under New Contract Printer Friendly Version
09/27/07Emergent BioSolutions Receives Development Contract from NIAID/BARDA to Fund Continued Development of Anthrax Therapeutic Printer Friendly Version
09/26/07Emergent BioSolutions Signs $448 Million Three Year Contract with Department of Health and Human Services Printer Friendly Version
08/20/07Emergent BioSolutions to Present at the Thomas Weisel Partners Healthcare Conference 2007 Printer Friendly Version
08/06/07Emergent BioSolutions Reports Financial Results for Second Quarter 2007 Printer Friendly Version
07/20/07Emergent BioSolutions to Release Second Quarter 2007 Financial Results on August 6, 2007; Management Will Conduct a Conference Call to Discuss Results as Well as Provide an Update on Business Developments Printer Friendly Version
07/03/07Emergent BioSolutions and HSBC Sign $30 Million Loan to Support Manufacturing Expansion Program Printer Friendly Version
06/27/07Emergent BioSolutions Anticipates 2nd Quarter BioThrax Revenues of Approximately $20 Million Based on Accelerated Delivery to Department of Defense Printer Friendly Version
06/20/07Emergent BioSolutions to Present at the Jefferies & Company Healthcare Conference Printer Friendly Version
06/15/07Emergent BioSolutions Announces Expansion of Board of Directors and Appointment of Dr. Sue Bailey to the Company's Board of Directors Printer Friendly Version
06/14/07Emergent BioSolutions Announces Results from Annual Meeting of Stockholders Printer Friendly Version
06/11/07Emergent BioSolutions to Hold Annual Meeting of Stockholders Printer Friendly Version
05/18/07Emergent BioSolutions to Present at Morgan Keegan Homeland Security Technology Conference 2007 Printer Friendly Version
05/16/07Emergent BioSolutions Announces Management Changes Printer Friendly Version
05/09/07Emergent BioSolutions Reports Financial Results for First Quarter 2007 Printer Friendly Version
05/01/07Emergent BioSolutions to Present at The Rodman and Renshaw 4th Annual Global Healthcare Conference Printer Friendly Version
04/25/07Emergent BioSolutions to Release First Quarter 2007 Financial Results on May 9, 2007 Printer Friendly Version
04/18/07Emergent BioSolutions Announces That Department of Health and Human Services and Department of Defense Issued Notices of Intent to Procure up to a Combined 22.75 Million Doses of BioThrax(R)(Anthrax Vaccine Adsorbed) Printer Friendly Version
03/22/07CORRECTING and REPLACING Emergent BioSolutions Reports Financial Results for 2006 Printer Friendly Version
03/22/07Emergent BioSolutions Announces Management Promotions Printer Friendly Version
03/22/07Emergent BioSolutions Reports Financial Results for 2006 Printer Friendly Version
03/21/07Emergent BioSolutions Files Investigational New Drug Application With FDA for Pivotal Anthrax Immune Globulin Clinical Trial Printer Friendly Version
03/15/07Emergent BioSolutions Gains Rights To VaxImmune(TM) From Coley Pharmaceutical Group to Expand Its Anthrax Franchise Printer Friendly Version
03/15/07Emergent BioSolutions to Host Conference Call on March 22, 2007 to Announce Fourth Quarter and Full Year 2006 Financial Results Printer Friendly Version
03/05/07Emergent BioSolutions to Present at the Cowen & Company 27th Annual Health Care Conference Printer Friendly Version
02/23/07Emergent BioSolutions Delivers Approximately 1 Million Doses of BioThrax(R) Ahead of Schedule to U.S. Department of Health and Human Services for Strategic National Stockpile Printer Friendly Version
02/22/07Emergent BioSolutions Remains Committed to Development of Enhanced Anthrax Countermeasures Printer Friendly Version
02/12/07FDA Grants Fast Track Designation to Emergent BioSolutions' BioThrax(R) for Post-Exposure Prophylaxis against Anthrax Infection Printer Friendly Version
01/30/07Emergent BioSolutions to Present at BIO CEO & Investor Conference Printer Friendly Version
01/08/07Emergent BioSolutions Announces Expected 2006 Total Revenue of Approximately $150 Million Printer Friendly Version